193 related articles for article (PubMed ID: 16197398)
41. [Fulminant acute hepatitis B after infliximab treatment in Crohn's disease].
Olfa H; Aroua G; Wissem M; Wafa BM; Hichem L; Nabil BC; Fethia B; Leila S
Tunis Med; 2014 May; 92(5):349-50. PubMed ID: 25504398
[No Abstract] [Full Text] [Related]
42. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?
Domènech E; Hinojosa J; Nos P; Garcia-Planella E; Cabré E; Bernal I; Gassull MA
Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1107-13. PubMed ID: 16305724
[TBL] [Abstract][Full Text] [Related]
43. Infliximab-induced acne: report of two cases.
Bassi E; Poli F; Charachon A; Claudepierre P; Revuz J
Br J Dermatol; 2007 Feb; 156(2):402-3. PubMed ID: 17223901
[No Abstract] [Full Text] [Related]
44. Guttate psoriasis induced by infliximab in a child with Crohn's disease.
Costa-Romero M; Coto-Segura P; Suarez-Saavedra S; Ramos-Polo E; Santos-Juanes J
Inflamm Bowel Dis; 2008 Oct; 14(10):1462-3. PubMed ID: 18383177
[No Abstract] [Full Text] [Related]
45. Infliximab-induced acne: report of a third case.
Sladden MJ; Clarke PJ; Mitchell B
Br J Dermatol; 2008 Jan; 158(1):172. PubMed ID: 17854357
[No Abstract] [Full Text] [Related]
46. The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease.
Moss AC; Fernandez-Becker N; Jo Kim K; Cury D; Cheifetz AS
Aliment Pharmacol Ther; 2008 Jul; 28(2):221-7. PubMed ID: 18485127
[TBL] [Abstract][Full Text] [Related]
47. [Development of tuberculosis after treatment with the TNF-alpha inhibitor infliximab].
Dahl M; Ravn P
Ugeskr Laeger; 2005 Jan; 167(5):527-8. PubMed ID: 15745179
[No Abstract] [Full Text] [Related]
48. Disseminated tuberculosis in a Crohn's disease patient on anti-TNF alpha therapy despite chemoprophylaxis.
Bourikas LA; Kourbeti IS; Koutsopoulos AV; Koutroubakis IE
Gut; 2008 Mar; 57(3):425; author reply 425-6. PubMed ID: 18268059
[No Abstract] [Full Text] [Related]
49. [A case of psoriasis induced by infliximab treatment for Crohn's disease].
Jwa YJ; Kim NH; Park HJ; Park JS; Bae WK; Kim KA; Lee JS; Moon YS
Korean J Gastroenterol; 2010 Nov; 56(5):324-8. PubMed ID: 21099241
[TBL] [Abstract][Full Text] [Related]
50. Development of diffuse alopecia with psoriasis-like eruptions during administration of infliximab for Crohn's disease.
Kawashima K; Ishihara S; Yamamoto A; Ohno Y; Fukuda K; Onishi K; Kinoshita Y
Inflamm Bowel Dis; 2013 Mar; 19(3):E33-4. PubMed ID: 22508420
[No Abstract] [Full Text] [Related]
51. Immortal time bias in estimates of mortality among infliximab-treated patients with Crohn's disease.
Lewis JD
Gut; 2010 Nov; 59(11):1586-7. PubMed ID: 20732919
[No Abstract] [Full Text] [Related]
52. Granulomatous pneumonitis, sclerosing cholangitis, and pancreatitis in a child with Crohn disease: response to infliximab.
Silbermintz A; Krishnan S; Banquet A; Markowitz J
J Pediatr Gastroenterol Nutr; 2006 Mar; 42(3):324-6. PubMed ID: 16540804
[No Abstract] [Full Text] [Related]
53. Babesiosis in a patient on infliximab for Crohn's disease.
Cullen G; Sands BE; Yajnik V
Inflamm Bowel Dis; 2010 Aug; 16(8):1269-70. PubMed ID: 19885904
[No Abstract] [Full Text] [Related]
54. Crohn's colitis presenting with node-negative colon cancer and liver metastasis after therapy with infliximab: report of two cases.
Nicholson T; Orangio GR; Brandenburg D; Wolf DC; Pennington EE
Dis Colon Rectum; 2005 Aug; 48(8):1651-5. PubMed ID: 15933793
[No Abstract] [Full Text] [Related]
55. [Listeria meningitis as complication of treatment with infliximab in a patient with Crohn's disease].
Osuna Molina R; Ferrer Ríos T; Gallego Gallegos R; Ramos Lora M; Ynfante Ferrús M; Figueruela López B
Rev Esp Enferm Dig; 2006 Jan; 98(1):60-1. PubMed ID: 16555939
[No Abstract] [Full Text] [Related]
56. Severe agranulocytosis following first infliximab infusion in Crohn's disease.
Rosales-Zábal JM; Fernández-Pérez F; Albandea-Moreno C; Vera-Rivero FM; Navarro-Jarabo JM
Inflamm Bowel Dis; 2011 Nov; 17(11):E147-8. PubMed ID: 21830280
[No Abstract] [Full Text] [Related]
57. Infliximab and the bone in Crohn's disease.
Kunisaki R; Chaki O; Taguchi T; Sugiyama T; Sugita A
Aliment Pharmacol Ther; 2005 Mar; 21(6):789-90. PubMed ID: 15771766
[No Abstract] [Full Text] [Related]
58. [Infliximab--practical guidelines for the treatment of Crohn's disease].
Bauerfeind P; Beglinger C; Beltinger J; Braegger C; Eigenmann F; Fried M; Guyot J; Hürlimann R; Michetti P; Seibold F; Straumann A
Rev Med Suisse; 2006 Jul; 2(74):1807-15. PubMed ID: 16927560
[TBL] [Abstract][Full Text] [Related]
59. Does administration of infliximab increase susceptibility to listeriosis?
Morelli J; Wilson FA
Am J Gastroenterol; 2000 Mar; 95(3):841-2. PubMed ID: 10710107
[No Abstract] [Full Text] [Related]
60. Severe anaphylactic reaction to infliximab in pediatric patients with Crohn's disease.
Diamanti A; Castro M; Papadatou B; Ferretti F; Gambarara M
J Pediatr; 2002 May; 140(5):636-7; author reply 637. PubMed ID: 12032538
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
